NCT05838521 is a Phase 2 clinical trial of Sacituzumab govitecan in Cervical Cancer, sponsored by Yale University.

Who is sponsoring NCT05838521?

NCT05838521 is sponsored by Yale University.

What drugs are being tested in NCT05838521?

Interventions in NCT05838521: Sacituzumab govitecan.

What condition does NCT05838521 study?

NCT05838521 studies Cervical Cancer.

Is NCT05838521 still recruiting?

NCT05838521 is currently recruiting now. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT05838521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Recruiting now Phase 2 Last updated 6 February 2026

What this trial tests

Phase 2 trial testing Sacituzumab govitecan in Cervical Cancer in 20 participants. Currently enrolling.

Timeline

2 June 2023

Primary endpoint
1 June 2026

1 June 2028

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	2 June 2023
Primary completion	1 June 2026
Estimated completion	1 June 2028
Sites	2 locations across United States

Drugs / interventions tested

Sacituzumab govitecan — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Yale University

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in cervical cancer: current insights and future directions.
Xu M, Cao C, Wu P, Huang X, et al · · 2025 · cited 55× · PMID 39611440 · DOI 10.1002/cac2.12629
Evolving standards and future directions for systemic therapies in cervical cancer.
Ang DJM, Chan JJ. · · 2024 · cited 14× · PMID 38282261 · DOI 10.3802/jgo.2024.35.e65
Antibody drug conjugates in the clinic.
Udofa E, Sankholkar D, Mitragotri S, Zhao Z. · · 2024 · cited 12× · PMID 39545074 · DOI 10.1002/btm2.10677
Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025.
Silverstein J, Karlan B, Herrington N, Konecny G. · · 2025 · cited 11× · PMID 39480912 · DOI 10.1097/gco.0000000000001002
Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
Chen B, Zheng X, Wu J, Chen G, et al · · 2025 · cited 4× · PMID 41184856 · DOI 10.1186/s12943-025-02489-2
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art.
Camarda F, Paderno M, Cannizzaro MC, Nero C, et al · · 2024 · cited 4× · PMID 39323928 · DOI 10.1177/17588359241277647
Exceptional response to trastuzumab deruxtecan in recurrent neuroendocrine cervical cancer: A case report.
Tostrud L, Howitt BE, Mills M, Karam A, et al · · 2025 · cited 2× · PMID 40678579 · DOI 10.1016/j.gore.2025.101798
Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies.
Reddy Y, Pai P, Das I, Nayak S, et al · · 2026 · PMID 41781859 · DOI 10.1186/s10020-026-01446-z

Verify or expand the search:

Other trials of Sacituzumab govitecan

Trials testing the same drug.

NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07178730 — NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple- · Phase 3 · not yet recruiting
NCT07011654 — Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) · Phase 1, PHASE2 · recruiting
NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05838521 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05838521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing